FDA approves Jardiance tabs

SILVER SPRING, Md. — The Food and Drug Administration announced approval for Jardiance (empagliflozin) tablets, which is to be used as an addition to diet and exercise to improve glycemic control in adults with Type 2 diabetes.



The drug is a sodium glucose co-transporter 2 (SGLT2) inhibitor. It works by blocking the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose levels in diabetics who have elevated blood glucose levels, the agency stated.



"Jardiance provides an additional treatment option for the care of patients with type 2 diabetes," said Curtis J. Rosebraugh, M.D., M.P.H., director of the Office of Drug Evaluation II in the FDA’s Center for Drug Evaluation and Research. “It can be used alone or added to existing treatment regimens to control blood sugar levels in the overall management of diabetes.”



Jardiance is distributed by Boehringer Ingelheim Pharmaceuticals.